表紙:細胞・遺伝子治療用融解装置の世界市場:産業動向・成長予測 (~2028年)
市場調査レポート
商品コード
1036309

細胞・遺伝子治療用融解装置の世界市場:産業動向・成長予測 (~2028年)

Global Cell And Gene Therapy Thawing Equipment Market - Industry Trends And Forecast To 2028

出版日: | 発行: Data Bridge Market Research Private Limited | ページ情報: 英文 292 Pages | 納期: 3~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
細胞・遺伝子治療用融解装置の世界市場:産業動向・成長予測 (~2028年)
出版日: 2021年09月01日
発行: Data Bridge Market Research Private Limited
ページ情報: 英文 292 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の細胞・遺伝子治療用融解装置の市場規模は予測期間中14.2%のCAGRで成長すると予測されています。細胞・遺伝子治療の開発に向けたR&D投資の増加、医療費の増加などの要因が同市場の成長を推進しています。

当レポートでは、世界の細胞・遺伝子治療用融解装置の市場を調査し、市場概要、市場成長への各種影響因子の分析、関連法規制、市場規模の推移・予測、モダリティ・サンプル・タイプ・用途・エンドユーザー・地域/主要国別の内訳、企業シェア、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 市場の分類

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 上流および下流プロセスでの融解装置の使用

第6章 融解装置を使用した細胞および遺伝子治療のワークフロー

第7章 世界の細胞・遺伝子治療用融解装置市場:法規制

第8章 地域の概要

第9章 市場概要

  • 促進要因
  • 抑制要因
  • 市場機会
  • 課題

第10章 COVID-19の影響

第11章 世界の細胞・遺伝子治療用融解装置市場:モダリティ別

  • ベンチトップ
  • ポータブル

第12章 世界の細胞・遺伝子治療用融解装置市場:サンプル別

  • 細胞治療
    • CAR T細胞
    • NK細胞
    • 間葉系幹細胞
    • TIL (腫瘍浸潤リンパ球)
    • その他
  • 遺伝子治療
    • アデノウイルス
    • アデノ随伴ウイルス
    • レンチウイルス
    • 腫瘍溶解性ウイルス
    • その他

第13章 世界の細胞・遺伝子治療用融解装置市場:タイプ別

  • 自動解凍システム
  • 手動解凍システム

第14章 世界の細胞・遺伝子治療用融解装置市場:用途別

  • 上流処理
    • 自動解凍システム
    • 手動解凍システム
  • 下流処理
    • 自動解凍システム
    • 手動解凍システム

第15章 世界の細胞・遺伝子治療用融解装置市場:エンドユーザー別

  • 病院・診断ラボ
  • 血液バンク・輸血センター
  • 研究ラボ・学術機関
  • バイオテクノロジー・製薬産業
  • 臍帯血・幹細胞バンク
  • 遺伝子バンク
  • その他

第16章 世界の細胞・遺伝子治療用融解装置市場:流通経路別

  • 直接入札
  • サードパーティ流通販売業者
  • その他

第17章 世界の細胞・遺伝子治療用融解装置市場:地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第18章 世界の細胞・遺伝子治療用融解装置市場:企業情勢

  • 企業シェア分析:世界
  • 企業シェア分析:北米
  • 企業シェア分析:欧州
  • 企業シェア分析:アジア太平洋

第19章 SWOT分析

第20章 企業プロファイル

  • MERCK KGAA
  • EPPENDORF AG
  • SARTORIUS AG
  • CYTIVA
  • BARKEY
  • BOEKEL SCIENTIFIC
  • BIOLINE INDIA
  • COOK
  • GENESIS BPS
  • HELMER SCIENTIFIC INC.
  • LABCOLD
  • PLEURISTEM THERAPEUTICS INC.
  • SARSTEDT AG & CO. KG

第21章 アンケート

第22章 関連レポート

図表

LIST OF FIGURES

  • FIGURE 1 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SEGMENTATION 38
  • FIGURE 2 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DATA TRIANGULATION 41
  • FIGURE 3 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DROC ANALYSIS 42
  • FIGURE 4 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 43
  • FIGURE 5 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: COMPANY RESEARCH ANALYSIS 43
  • FIGURE 6 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: MULTIVARIATE MODELLING 44
  • FIGURE 7 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: INTERVIEW DEMOGRAPHICS 46
  • FIGURE 8 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: DBMR MARKET POSITION GRID 47
  • FIGURE 9 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: VENDOR SHARE ANALYSIS 48
  • FIGURE 10 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: MARKET APPLICATION COVERAGE GRID 49
  • FIGURE 11 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SEGMENTATION 53
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028 54
  • FIGURE 13 INCREASE IN CASES OF GENETIC DISEASES SUCH AS CARDIAC AILMENTS, CYSTIC FIBROSIS AND AIDS IS EXPECTED TO DRIVE THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028 55
  • FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET IN 2021 & 2028 55
  • FIGURE 15 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE CELL AND GENE THERAPY THAWING EQUIPMENT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028 56
  • FIGURE 16 PESTEL ANALYSIS 57
  • FIGURE 17 PORTERS FIVE FORCES MODEL 58
  • FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET 67
  • FIGURE 19 INCIDENCE OF CYSTIC FIBROSIS OBSERVED IN THE COUNTRIES 69
  • FIGURE 20 PREVALENCE OF SICKLE CELL ANEMIA IN AFRICA AND EUROPE 69
  • FIGURE 21 NEW CANCER CASES WORLDWIDE, (2018) (IN MILLION) 73
  • FIGURE 22 GLOBAL CANCER INCIDENCE (2018) 74
  • FIGURE 23 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, 2020 82
  • FIGURE 24 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, 2021-2028 (USD MILLION) 83
  • FIGURE 25 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, CAGR (2021-2028) 83
  • FIGURE 26 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY, LIFELINE CURVE 84
  • FIGURE 27 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, 2020 88
  • FIGURE 28 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, 2021-2028 (USD MILLION) 89
  • FIGURE 29 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY SAMPLE, CAGR (2021-2028) 89
  • FIGURE 30 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY SAMPLE, LIFELINE CURVE 90
  • FIGURE 31 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, 2020 96
  • FIGURE 32 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, 2021-2028 (USD MILLION) 97
  • FIGURE 33 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET : BY TYPE, CAGR (2021-2028) 97
  • FIGURE 34 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY TYPE, LIFELINE CURVE 98
  • FIGURE 35 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, 2020 102
  • FIGURE 36 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, 2021-2028 (USD MILLION) 103
  • FIGURE 37 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, CAGR (2021-2028) 103
  • FIGURE 38 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY APPLICATION, LIFELINE CURVE 104
  • FIGURE 39 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, 2020 108
  • FIGURE 40 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, 2021-2028 (USD MILLION) 109
  • FIGURE 41 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, CAGR (2021-2028) 109
  • FIGURE 42 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY END USER, LIFELINE CURVE 110
  • FIGURE 43 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2020 119
  • FIGURE 44 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION) 120
  • FIGURE 45 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028) 120
  • FIGURE 46 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 121
  • FIGURE 47 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 126
  • FIGURE 48 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2020) 127
  • FIGURE 49 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2021 & 2028) 127
  • FIGURE 50 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY REGION (2020 & 2028) 128
  • FIGURE 51 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 128
  • FIGURE 52 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 131
  • FIGURE 53 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 132
  • FIGURE 54 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 132
  • FIGURE 55 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 133
  • FIGURE 56 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 133
  • FIGURE 57 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 147
  • FIGURE 58 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 148
  • FIGURE 59 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 148
  • FIGURE 60 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 149
  • FIGURE 61 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 149
  • FIGURE 62 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 188
  • FIGURE 63 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 189
  • FIGURE 64 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 189
  • FIGURE 65 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 190
  • FIGURE 66 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 190
  • FIGURE 67 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 226
  • FIGURE 68 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 227
  • FIGURE 69 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 227
  • FIGURE 70 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 228
  • FIGURE 71 SOUTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 228
  • FIGURE 72 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: SNAPSHOT (2020) 240
  • FIGURE 73 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020) 241
  • FIGURE 74 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2021 & 2028) 241
  • FIGURE 75 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY COUNTRY (2020 & 2028) 242
  • FIGURE 76 MIDDLE EAST AND AFRICA CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: BY MODALITY (2021-2028) 242
  • FIGURE 77 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 262
  • FIGURE 78 NORTH AMERICA CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 263
  • FIGURE 79 EUROPE CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 264
  • FIGURE 80 ASIA-PACIFIC CELL AND GENE THERAPY THAWING EQUIPMENTMARKET: COMPANY SHARE 2020 (%) 265
  • FIGURE 81 COMPANY SHARE ANALYSIS 268
  • FIGURE 82 COMPANY SHARE ANALYSIS 271
  • FIGURE 83 COMPANY SHARE ANALYSIS 274
  • FIGURE 84 COMPANY SHARE ANALYSIS 276
目次

Global cell and gene therapy thawing equipment market is projected to register a CAGR of 14.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:

Global Cell and Gene Therapy Thawing Equipment Market, By Modality (Benchtop and Portable), Sample (Cell Therapies and Gene Therapies), Type (Manual Thawing System and Automatic Thawing System), Application (Upstream Processing and Downstream Processing), End User (Blood Banks And Transfusion Centres, Hospitals and Diagnostic Laboratories, Research Laboratories And Academic Institutes, Biotechnology and Pharmaceutical Industry, Cord Blood and Stem Cell Banks, Gene Banks and Others), Distribution Channel (Direct Tender, Third Part Distributor and Others), Country (U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Belgium, Turkey, Ireland, Rest of Europe, China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa, Brazil, Argentina and Rest of South America) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the global cell and gene therapy thawing equipment market are:

  • Rise in investment in research and development for development of cell and gene therapies
  • Rising healthcare expenditure

Market Players:

The key market players for global cell and gene therapy thawing equipment market are listed below:

  • Pluristem Therapeutics Inc.
  • Genesis BPS
  • Eppendorf AG
  • Cytiva (A subsidiary of Danaher Corporation)
  • Glenmark Pharmaceutical Inc.
  • USA (A subsidiary of Glenmark)
  • EDGE pharma
  • Cook
  • SARSTEDT AG & Co. KG
  • Barkey
  • Boekel Scientific
  • LABCOLD
  • Sartorious AG
  • Helmer Scientific Inc.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 VENDOR SHARE ANALYSIS
  • 2.11 MARKET APPLICATION COVERAGE GRID
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 USAGE OF THAWING EQUIPMENT IN UPSTREAM AND DOWNSTREAM PROCESSES

  • 5.1 UPSTREAM PROCESS
  • 5.2 DOWNSTREAM PROCESS

6 CELL AND GENE THERAPY WORKFLOW USING THAWING EQUIPMENT

7 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET: REGULATIONS

  • 7.1 CANADA
  • 7.2 THE U.S.
  • 7.3 EUROPE
  • 7.4 GENE THERAPY LEGISLATION IN AUSTRIA
  • 7.5 GENE THERAPY LEGISLATION IN BULGARIA
  • 7.6 JAPAN
  • 7.7 ITALY
  • 7.8 MALAYSIA

8 REGIONAL SUMMARY

9 MARKET OVERVIEW

  • 9.1 DRIVERS
    • 9.1.1 INCREASE IN CASES OF GENETIC DISEASES SUCH AS CYSTIC FIBROSIS AND SICKLE CELL ANEMIA
    • 9.1.2 RISE IN INVESTMENT IN R&D FOR DEVELOPMENT OF CELL AND GENE THERAPIES
    • 9.1.3 GOVERNMENT INITIATIVES FOR INITIATION OF CELL AND GENE THERAPY FIELD
    • 9.1.4 INCREASED IMPLEMENTATION OF ADENO-ASSOCIATED VIRUS
    • 9.1.5 TECHNOLOGICAL ADVANCEMENTS IN THE THAWING SYSTEMS
  • 9.2 RESTRAINTS
    • 9.2.1 RISE IN COST ASSOCIATED WITH CELL AND GENE THERAPY ENGINEERING
    • 9.2.2 RISE OF UNWANTED MUTAGENS
    • 9.2.3 TECHNICAL HINDRANCE FACED IN USING THAWING INSTRUMENTS
    • 9.2.4 STRICT REGULATORY FRAMEWORK
  • 9.3 OPPORTUNITIES
    • 9.3.1 INCREASING PREVALENCE OF CANCER
    • 9.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
    • 9.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR
  • 9.4 CHALLENGES
    • 9.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES
    • 9.4.2 LACK OF ACCESSIBILITY

10 IMPACT OF COVID-19 ON GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET

  • 10.1 IMPACT ON PRICE
  • 10.2 IMPACT ON DEMAND
  • 10.3 IMPACT ON SUPPLY CHAIN
  • 10.4 STRATEGIC DECISION FOR MANUFACTURERS
  • 10.5 CONCLUSION

11 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY MODALITY

  • 11.1 OVERVIEW
  • 11.2 BENCH TOP
  • 11.3 PORTABLE

12 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY SAMPLE

  • 12.1 OVERVIEW
  • 12.2 CELL THERAPIES
    • 12.2.1 CAR T CELLS
    • 12.2.2 NK CELLS
    • 12.2.3 MSCS
    • 12.2.4 TILS
    • 12.2.5 OTHERS
  • 12.3 GENE THERAPIES
    • 12.3.1 ADENOVIRUS
    • 12.3.2 ADENO-ASSOCIATED VIRUSES
    • 12.3.3 LENTIVIRUSES
    • 12.3.4 ONCOLYTIC VIRUSES
    • 12.3.5 OTHERS

13 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY TYPE

  • 13.1 OVERVIEW
  • 13.2 AUTOMATIC THAWING SYSTEM
  • 13.3 MANUAL THAWING SYSTEM

14 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY APPLICATION

  • 14.1 OVERVIEW
  • 14.2 UPSTREAM PROCESSING
    • 14.2.1 AUTOMATIC THAWING SYSTEM
    • 14.2.2 MANUAL THAWING SYSTEM
  • 14.3 DOWNSTREAM PROCESSING
    • 14.3.1 AUTOMATIC THAWING SYSTEM
    • 14.3.2 MANUAL THAWING SYSTEM

15 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY END USER

  • 15.1 OVERVIEW
  • 15.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
  • 15.3 BLOOD BANKS AND TRANSFUSION CENTERS
  • 15.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES
  • 15.5 BIOTECHNOLOGY AND PHARMACEUTICAL INDUSTRY
  • 15.6 CORD BLOOD AND STEM CELL BANKS
  • 15.7 GENE BANKS
  • 15.8 OTHERS

16 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY DISTRIBUTION CHANNEL

  • 16.1 OVERVIEW
  • 16.2 DIRECT TENDER
  • 16.3 THIRD PARTY DISTRIBUTORS
  • 16.4 OTHERS

17 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, BY REGION

  • 17.1 OVERVIEW
  • 17.2 NORTH AMERICA
    • 17.2.1 U.S.
    • 17.2.2 CANADA
    • 17.2.3 MEXICO
  • 17.3 EUROPE
    • 17.3.1 GERMANY
    • 17.3.2 FRANCE
    • 17.3.3 U.K.
    • 17.3.4 ITALY
    • 17.3.5 SPAIN
    • 17.3.6 RUSSIA
    • 17.3.7 TURKEY
    • 17.3.8 BELGIUM
    • 17.3.9 NETHERLANDS
    • 17.3.10 SWITZERLAND
    • 17.3.11 LUXEMBOURG
    • 17.3.12 REST OF EUROPE
  • 17.4 ASIA-PACIFIC
    • 17.4.1 CHINA
    • 17.4.2 INDIA
    • 17.4.3 JAPAN
    • 17.4.4 SOUTH KOREA
    • 17.4.5 AUSTRALIA
    • 17.4.6 SINGAPORE
    • 17.4.7 THAILAND
    • 17.4.8 MALAYSIA
    • 17.4.9 INDONESIA
    • 17.4.10 PHILIPPINES
    • 17.4.11 REST OF ASIA PACIFIC
  • 17.5 SOUTH AMERICA
    • 17.5.1 BRAZIL
    • 17.5.2 ARGENTINA
    • 17.5.3 REST OF SOUTH AMERICA
  • 17.6 MIDDLE EAST AND AFRICA
    • 17.6.1 SOUTH AFRICA
    • 17.6.2 SAUDI ARABIA
    • 17.6.3 U.A.E.
    • 17.6.4 EGYPT
    • 17.6.5 ISRAEL
    • 17.6.6 REST OF MIDDLE EAST AFRICA

18 GLOBAL CELL AND GENE THERAPY THAWING EQUIPMENT MARKET, COMPANY LANDSCAPE

  • 18.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 18.3 COMPANY SHARE ANALYSIS: EUROPE
  • 18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 SWOT ANALYSIS

20 COMPANY PROFILE

  • 20.1 MERCK KGAA
    • 20.1.1 COMPANY SNAPSHOT
    • 20.1.2 REVENUE ANALYSIS
    • 20.1.3 PRODUCT PORTFOLIO
    • 20.1.4 RECENT DEVELOPMENTS
  • 20.2 EPPENDORF AG
    • 20.2.1 COMPANY SNAPSHOT
    • 20.2.2 REVENUE ANALYSIS
    • 20.2.3 PRODUCT PORTFOLIO
    • 20.2.4 RECENT DEVELOPMENTS
  • 20.3 SARTORIUS AG
    • 20.3.1 COMPANY SNAPSHOT
    • 20.3.2 REVENUE ANALYSIS
    • 20.3.3 PRODUCT PORTFOLIO
    • 20.3.4 RECENT DEVELOPMENT
  • 20.4 CYTIVA (A SUBSIDIARY OF DANAHER CORPORATION)
    • 20.4.1 COMPANY SNAPSHOT
    • 20.4.2 REVENUE ANALYSIS
    • 20.4.3 PRODUCT PORTFOLIO
    • 20.4.4 .RECENT DEVELOPMENTS
  • 20.5 BARKEY
    • 20.5.1 COMPANY SNAPSHOT
    • 20.5.2 PRODUCT PORTFOLIO
    • 20.5.3 RECENT DEVELOPMENTS
  • 20.6 BOEKEL SCIENTIFIC
    • 20.6.1 COMPANY SNAPSHOT
    • 20.6.2 PRODUCT PORTFOLIO
    • 20.6.3 RECENT DEVELOPMENT
  • 20.7 BIOLINE INDIA
    • 20.7.1 COMPANY SNAPSHOT
    • 20.7.2 PRODUCT PORTFOLIO
    • 20.7.3 RECENT DEVELOPMENTS
  • 20.8 COOK
    • 20.8.1 COMPANY SNAPSHOT
    • 20.8.2 PRODUCT PORTFOLIO
    • 20.8.3 RECENT DEVELOPMENT
  • 20.9 GENESIS BPS
    • 20.9.1 COMPANY SNAPSHOT
    • 20.9.2 PRODUCT PORTFOLIO
    • 20.9.3 RECENT DEVELOPMENTS
  • 20.10 HELMER SCIENTIFIC INC.
    • 20.10.1 COMPANY SNAPSHOT
    • 20.10.2 PRODUCT PORTFOLIO
    • 20.10.3 RECENT DEVELOPMENTS
  • 20.11 LABCOLD
    • 20.11.1 COMPANY SNAPSHOT
    • 20.11.2 PRODUCT PORTFOLIO
    • 20.11.3 RECENT DEVELOPMENTS
  • 20.12 PLEURISTEM THERAPEUTICS INC.
    • 20.12.1 COMPANY SNAPSHOT
    • 20.12.2 REVENUE ANALYSIS
    • 20.12.3 PRODUCT PORTFOLIO
    • 20.12.4 RECENT DEVELOPMENTS
  • 20.13 SARSTEDT AG & CO. KG
    • 20.13.1 COMPANY SNAPSHOT
    • 20.13.2 PRODUCT PORTFOLIO
    • 20.13.3 RECENT DEVELOPMENTS

21 QUESTIONNAIRE

22 RELATED REPORTS